Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis
Long-term Rl therapy beyond 18-24 months leads to sustained disease remission in RP, and therapy withdrawal is associated with a recurrence in two-thirds of patients. A strategy that involves a gradual taper of RI therapy appears to be associated with a relatively lower risk of disease recurrence compared with discontinuation without tapering. Larger-scale, multicentre studies with extended follow-up periods are warranted to elucidate optimal treatment durations and to establish standardised cessation protocols.
Authors
- Larisa G. Tereshchenko (ORCID: https://orcid.org/0000-0002-6976-1313)
- Jaideep Singh Bhalla (ORCID: https://orcid.org/0000-0001-5776-7761)
- Paul C Cremer (ORCID: https://orcid.org/0000-0002-0794-3306)
- Allan L. Klein (ORCID: https://orcid.org/0000-0001-9240-8369)
- Alveena Batool Syed
- Antonio Abbate (ORCID: https://orcid.org/0000-0002-1930-785X)
- Massimo Imazio (ORCID: https://orcid.org/0000-0002-5722-0245)
- Ushasi Saraswati (ORCID: https://orcid.org/0000-0001-8529-6493)
- Tom Kai Ming Wang (ORCID: https://orcid.org/0000-0001-5570-9402)
- Mary Heine
Institutions
- Northwestern University (US)
- Cleveland Clinic (US)
- Johns Hopkins University (US)
- Virginia Commonwealth University (US)
- Commonwealth Computer Research (United States) (US)
- Ospedale Santa Maria della Misericordia di Udine (IT)
Publication Details
- Journal
- Heart
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1136/heartjnl-2024-325515
- Citations
- 1
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 1.39